Compare Tilray Brands Inc (TLRY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Thomson Reuters Corp — how do they compare? Tilray Brands Inc trades at $4.21 (market cap $577.15M), while Thomson Reuters Corp trades at $97 (market cap $42.12B). The key difference: Thomson Reuters Corp is far larger — about 73× Tilray Brands Inc's market cap, and Thomson Reuters Corp pays a 2.7% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | TRI | |
|---|---|---|
Market Cap | $577.15M | $42.12B |
Sector | Health | Industrials |
52-Week High | $21.00 | $173.48 |
52-Week Low | $3.88 | $76.55 |
Enterprise Value | $744.29M | $44.73B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
Thomson Reuters (TRI) trades at $98.81, down 6.5% recently, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.99 per share and revenue growth of 9% year-over-year. Recent news highlights AI expansion with the launch of its proprietary LLM 'Thomson' and a cybersecurity incident affecting its case management system. Valuation ratios include a P/E of 26.03 and net income margin of 21.22%, indicating robust profitability but premium pricing.
Outlook is mixed: analyst consensus is bullish with a $113 price target, but technical weakness and cybersecurity risks pose headwinds. Investment opportunity lies in TRI's recurring revenue model and AI-driven growth, while risks include execution challenges and market sentiment shifts. The stock's current dip may offer a entry point for long-term investors focused on sustainable tech adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
